hydrochlorothiazide + captopril + nitrendipine + aspirin

This is a fixed-dose combination of four small molecule drugs, each with distinct mechanisms of action, primarily used for cardiovascular indications such as hypertension and prevention of cardiovascular events. - **Hydrochlorothiazide** is a thiazide diuretic that reduces blood pressure by increasing renal excretion of sodium and water, thereby decreasing plasma volume[1][3][5]. - **Captopril** is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation[1][3][4]. - **Nitrendipine** is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle and myocardium, resulting in vasodilation and reduced peripheral resistance[8]. - **Aspirin** (acetylsalicylic acid) irreversibly inhibits cyclooxygenase enzymes (COX-1/COX-2), reducing thromboxane A2 production and thus platelet aggregation; it is widely used for secondary prevention of cardiovascular events. The combination targets multiple pathways involved in hypertension and cardiovascular risk—volume overload (diuretic), renin–angiotensin system activation (ACE inhibitor), increased vascular tone (calcium channel blocker), and thrombosis/inflammation (aspirin). Such multi-drug regimens are sometimes considered in high-risk patients or those with resistant hypertension or established cardiovascular disease.